Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Seminoma 1Sarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Ovarian Neoplasms 1Osteolysis 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Melanoma 1Malignant Solid Tumour 1Hypercalcemia 1Hematologic Neoplasms 1Fractures, Spontaneous 1Colorectal Neoplasms 1Carcinoma 1Bone Diseases, Metabolic 1Anemia 1Amyloidosis 1

Interventions

Paclitaxel 3Ifosfamide 3Filgrastim 2Etoposide 2Carboplatin 2pegfilgrastim 1Thiotepa 1Sunitinib 1Mesna 1Granulocyte Colony-Stimulating Factor 1Cisplatin 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Seminoma × ARQ 197 × Clear all
NCT01055067 2021-04-06

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Daiichi Sankyo

Phase 2 Terminated
27 enrolled 6 charts

Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡